Bad news trumps good for MA, AstraZeneca

In a good news/bad news scenario, Massachusetts is getting the bad news first: AstraZeneca will be cutting 113 jobs at its manufacturing plant in Westborough, about 30 miles west of Boston. Cuts begin in October as the big pharma fights generics-maker Apotex, which is producing a knockoff of AZ's Pulmicort Respules asthma drug, says the Boston Globe.

The good news for the Bay State: AstraZeneca expects to open its expanded research facilities in Waltham, a Boston suburb, in November. The expansion brings the facility to 514,000 square feet from its former 380,000.

And some bad news for AZ (and MedImmune, GlaxoSmithKline and Novartis): swine-flu vaccine developer Serum Institute of India says it is "likely" to sell its vaccine for "one-fifth to one-tenth the cost of similar vaccines being made in Western economies," says a Wall Street Journal report.

- here's the Boston Globe article
- read the Wall Street Journal item


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.